Pleural space infections are increasing in incidence and continue to have high associated
morbidity, mortality, and need for invasive treatments such as thoracic surgery. The …

Background More than 30% of patients with pleural infection either die or require surgery.
Drainage of infected fluid is key to successful treatment, but intrapleural fibrinolytic therapy …

The use of intrapleural therapy with tissue plasminogen activator and DNase improves
outcomes in patients with complicated pleural space infections. However, little data exists for …

Rationale: Intrapleural tissue plasminogen activator (tPA)/deoxyribonuclease (DNase)
therapy for pleural infection given at the time of diagnosis has been shown to significantly …

Pleural infection is a common condition encountered by respiratory physicians and thoracic
surgeons alike. The European Respiratory Society (ERS) and European Society of Thoracic …

Rationale: Intrapleural therapy with a combination of tissue plasminogen activator (tPA) 10
mg and DNase 5 mg administered twice daily has been shown in randomized and open …

Pleural infection: what we need to know but don’t : Current Opinion in Pulmonary Medicine
Pleural infection: what we need to know but don’t : Current Opinion in Pulmonary Medicine Log …

Pleural infection is a millennia-spanning condition that has proved challenging to treat over
many years. Fourteen percent of cases of pneumonia are reported to present with a pleural …

Introduction: Pleural infection is a condition that continues to pose a significant challenge to
respiratory physicians. We hypothesize that the main barriers to progress include limited …

Pleural infection remains a global health burden associated with significant morbidity.
Drainage of the infected pleural fluid is important but can often be hindered by septations …